47 results on '"Alonso-Gordoa T"'
Search Results
2. Recommendations on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Patient Selection
3. Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study
4. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
5. Surgical and postsurgical management of abdominal paragangliomas and pheochromocytomas
6. Manejo quirúrgico y posquirúrgico de paragangliomas abdominales y feocromocitomas
7. 147P Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
8. 1645O Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial
9. 1659TiP A Spanish observational study for MOLecular characterization of THYroid carcinoma: MOLTHY Project – TTCC-2020-02
10. 496MO Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin
11. 1338P Cost-effectiveness and direct impact analysis of clinical research in the clinical approach of metastatic renal cell carcinoma and neuroendocrine tumors in a large public Spanish university hospital
12. COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)
13. Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
14. Impact on survival outcomes of poorly controlled hypertension after initiation of abiraterone/enzalutamide in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)
15. Management of metastatic prostate cancer in older patients
16. 1098O Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)
17. 666P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A
18. 676P CABOPRE: A phase II study of cabozantinib (cabo) prior cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)
19. 572P Potential impact of molecularly-selected treatment in patients with endocrine neoplasms at a tertiary university hospital
20. 1107P Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601)
21. 1099MO Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)
22. 1097O The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs
23. PD-0913 Local treatment to the primary tumor and PSA changes as prognostic factors in mCRPC
24. Protocol for presurgical and anesthetic management of pheochromocytomas and sympathetic paragangliomas: a multidisciplinary approach
25. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
26. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group
27. Durvalumab plus tremelimumab for the treatment of patients (pts) with refractory and progressive advanced thyroid carcinoma: A phase II multicohort trial (DUTHY / GETNE T1812)
28. SUNitinib with EVOfosfamide (TH-302) for G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve for systemic treatment. The SUNEVO phase II trial of the Spanish task force group for neuroendocrine and endocrine tumours (GETNE)
29. Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
30. First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A
31. Incidence of urological complications in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first line abiraterone and enzalutamide
32. Survival impact of the management of medical and urological complications during treatment with 1st line abiraterone (A) or enzalutamide (E) in patients with metastatic castration-resistant prostate cancer (mCRPC)
33. Prostate volume reduction in patients treated with Abiraterone and Enzalutamide: The forgotten outcome in Clinical trials
34. KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)
35. Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with durvalumab plus monalizumab (anti-NKG2A)
36. Efficacy of therapies after progression to up-front docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC)
37. Prognostic and predictive role of the PI3K–AKT–mTOR pathway in neuroendocrine neoplasms
38. A phase II trial of palbociclib in metastatic grade 1/2 pancreatic neuroendocrine tumors: The PALBONET study on behalf of the Spanish Taskforce Group of Neuroendocrine Tumors (GETNE)
39. Bruton’s tyrosine kinase (BTK) as a promising target in solid tumors
40. Mejoría en la calidad del manejo de los pacientes tras la implementación de un comité multidisciplinar de tumores endocrinos: análisis de la experiencia de 5 años
41. Early responses to enzalutamide in AR-V7 positive first line metastatic castration-resistant prostate cancer (mCRPC). A prospective SOGUG clinical trial: The PREMIERE study
42. 2566 Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC) real data in real life
43. 2540 Experience with radium-223 as a systemic treatment for patients (pts) with castration-resistant prostate cancer (CRPC) out of a clinical trial in Spain
44. New Challenges in Kidney Cancer Management: Integration of Surgery and Novel Therapies
45. GEP–NETs UPDATE: Biotherapy for neuroendocrine tumours
46. Advances in thyroid cancer treatment: latest evidence and clinical potential
47. Safety and Efficacy of Vandetanib As Systemic Treatment for Patients with Advanced and Progressive Medullary Thyroid Cancer (Mtc)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.